Abelacimab, formerly known as MAA868, represents a groundbreaking approach to treating thrombosis. This blood-thinning agent is a targeted monoclonal antibody that prevents the integrin αIIbβ3, a essential player in https://roryaepl532615.blogdigy.com/abelacimab-maa868-a-deep-investigation-into-the-new-thrombosis-treatment-66287030